Since 9/11, the U.S. government and the private sector have devised sophisticated ways of protecting people and assets. The threats have evolved, however, becoming more insidious. They no longer comprise just terrorists who target critical infrastructures. They also include insider threats, such as PFC Manning and NSA contractor Snowden who leaked classified defense information, active shooter incidents like the Sandy Hook Elementary School massacre, and the 2013 Boston Marathon terrorist bombing. These events make it imperative for the public and private sectors to engage in effective partnership to protect people, facilities, and national infrastructure assets. Homeland Security and Private Sector Business: Corporations' Role in Critical Infrastructure Protection, Second Edition identifies the role the private sector plays in securing our homeland and offers strategies to aid in the fight against national and international threats. Addressing mandates and legislation introduced since the first edition, this new edition includes: Updates to the NIPP (National Infrastructure Protection Plan) New case studies of both proper security policies and procedures in practice versus costly security breaches Greater focus on smaller business and practical "immediate use" guidance New measures for assessing and addressing vulnerabilities and threats New appendices with sample plans and practical checklists Supplying tools that can easily be adapted and applied to every business situation at all budget levels, the book helps businesses counter the total threat, from traditional terrorists to inside betrayers-providing a clear blueprint for securing people and assets.

Since its initial publication in 1993, Development and Evaluation of Drugs from Laboratory through Licensure to Market has been used as a textbook and reference for scientists in biomedical research, industry, and regulatory agencies. Updated and expanded, this second edition examines recent advances in scientific and regulatory approaches as well as changes in the way in which drugs are discovered, developed, and evaluated. The information provided outlines critical steps beginning from drug discovery in the laboratory to licensure and approval for market.

Biomedical research is an intrinsically changing and evolving field. A more direct strategy for drug discovery has gradually replaced random screening of natural products. More rapid identification of key molecular structures for new drug candidates and characterization of biomolecules including proteins, polysaccharides, and nucleic acids are now possible. The ability to chemically modify cell surfaces and carbohydrate linkages has facilitated designs of the next generation of new drugs. Thoroughly discussing these issues and more, Development and Evaluation of Drugs from Laboratory through Licensure to Market, Second Edition focuses on the latest developments in the science and regulation of bringing new drugs to market, including activities of the International Commission on Harmonization.

Since 9/11, the U.S. government and the private sector have devised sophisticated ways of protecting people and assets. The threats have evolved, however, becoming more insidious. They no longer comprise just terrorists who target critical infrastructures. They also include insider threats, such as PFC Manning and NSA contractor Snowden who leaked classified defense information, active shooter incidents like the Sandy Hook Elementary School massacre, and the 2013 Boston Marathon terrorist bombing. These events make it imperative for the public and private sectors to engage in effective partnership to protect people, facilities, and national infrastructure assets. Homeland Security and Private Sector Business: Corporations' Role in Critical Infrastructure Protection, Second Edition identifies the role the private sector plays in securing our homeland and offers strategies to aid in the fight against national and international threats. Addressing mandates and legislation introduced since the first edition, this new edition includes: Updates to the NIPP (National Infrastructure Protection Plan) New case studies of both proper security policies and procedures in practice versus costly security breaches Greater focus on smaller business and practical "immediate use" guidance New measures for assessing and addressing vulnerabilities and threats New appendices with sample plans and practical checklists Supplying tools that can easily be adapted and applied to every business situation at all budget levels, the book helps businesses counter the total threat, from traditional terrorists to inside betrayers-providing a clear blueprint for securing people and assets.

The pharmaceutical industry is on the verge of an exciting and challenging century. Advances in pharmaceutical sciences have dramatically changed the processes of discovery and development of new therapeutic drugs and, in turn, resulted in an extraordinary increase in the potential prophylactic and therapeutic interventions. In this atmosphere, an intimate understanding of the mechanisms of pharmacokinetic and pharmacodynamic activity and the processes of drug evaluation is essential.

Clinical Trials of Drugs and Biopharmaceuticals provides an overview of current procedures and major issues involved in drug and biopharmaceutical development. The book examines critical biochemical and pharmaceutical considerations for trials conducted during each phase of clinical development. It also reports information related to early pre-clinical evaluations of pharmacological activities and safety before proceeding with initiation of clinical trials. The sections focus on clinical assessments of drugs and biopharmaceuticals such as cardiovascular, respiratory, central nervous system, gastrointestinal and liver, genitourinary, skin, metabolism, and chemotherapeutic drugs as well as vaccines, biotechnology-derived therapeutics, and plant-based medicines.

Practical and informative, this step-by-step guide includes information on all four phases of clinical trials prior to licensure and covers the design of post-marketing studies. The editors examine how recent advances and increased demand for safer and more effective drugs have changed the process by which drugs are developed and approved.